Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Lucas Research Inc

Neither a doctor nor a teaching hospital

Research payments

$11,227,110

407 payments

Through program year 2025, Lucas Research Inc is reported as receiving $11,227,110 in research payments, across 407 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $4,698,726 189
2024 Research $2,463,103 131
2023 Research $1,740,903 44
2022 Research $1,347,514 17
2021 Research $888,613 20
2020 Research $88,250 6

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $4,247,413 65 payments
  2. AbbVie, Inc. $3,271,043 103 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,481,212 8 payments
  4. Novartis Pharmaceuticals Corporation $750,353 11 payments
  5. GlaxoSmithKline, LLC. $334,454 77 payments
  6. Madrigal Pharmaceuticals $327,065 54 payments
  7. Moderna TX, Inc. $326,079 48 payments
  8. Novavax Inc $314,485 14 payments
  9. IBSA Institut Biochimique SA $81,250 5 payments
  10. Lexicon Pharmaceuticals, Inc. $40,028 4 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $2,479,085 53 payments
  2. Ph IIb dose finding vs placebo in patients with Ob $702,019 2 payments
  3. A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naive Adults With Type 2 Diabetes $595,027 3 payments
  4. A Randomized, Placebo-controlled, Participant-and-investigator- Blinded, Sponsor Open-label Study to Evaluate the Safety, Tolerability, and Efficacy With Different Dosing Regimens of Subcutaneously Administered MBL949 in Obese Participants With or Without Type 2 Diabetes Mellitus $590,363 2 payments
  5. A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With Ly3549492 Once Daily Compared With Placebo in Adult Participants With Obesity Or Overweight $563,909 3 payments
  6. Phase 2 Study With Combination of Vemurafenib With Cobimetinib in B-Raf V600e/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab Therapy $418,500 4 payments
  7. A Phase 3 Parallel-Design Open-Label Randomized Control Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naive Adults With Type 2 Diabetes $408,691 1 payment
  8. Phase II study of BI456906 patients with T2DM Obes $367,122 3 payments
  9. POCC in NASH $361,110 2 payments
  10. 17 B-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatme $334,454 77 payments
What the money was spent on Research payments · program years 2020–2025
  1. Patient care $11,873 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record